Search
for

    Community Join

    5 / 312 results

      community (Europe) looking for advice on topical anti androgen use

       3 upvotes 1 year ago
      The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.

      community Any good place to buy KX-826, AHK‑Cu and PTD-DBM?

       1 upvotes 5 months ago
      The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

      community By when would pp405 be available in the grey market?

      in Chat  15 upvotes 6 months ago
      PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

      community The Cure isn't 5 years away; it's already here.

      in Research/Science  1005 upvotes 1 year ago
      PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

    Research

    5 / 1000+ results

    Learn

    1 / 800 results

      learn KX-826

      • Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical and is not approved as a medicine anywhere. Its first China Phase III trial did not beat placebo; the company reported in March 2026 that a later Phase III of a 1.0% formulation met its primary endpoint, but these results are company announcements, not peer-reviewed, and long-term safety is unknown.